Trial site
Johannesburg
Johannesburg, 2092, South AfricaNot linked to an institution yet
- 8running trials
- 4closed trials
The trials here
What the 12 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 25 trials
- Phase 1/21 trial
- Status
- Active, not recruiting6 trials
- Completed3 trials
- Recruiting2 trials
- Terminated1 trial
- Lead sponsor
- GlaxoSmithKline6 trials
- ViiV Healthcare6 trials
Running trials
Recruiting
A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment
NCT07393659· Phase 3· ViiV Healthcare· Source
Contact: Faeezah Patel (principal investigator)
Active, not recruiting
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
NCT06537414· Phase 2· GlaxoSmithKline· Source
Recruiting
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
NCT06613698· Phase 2· GlaxoSmithKline· Source
Contact: Nazeer Chopdat (principal investigator)
Active, not recruiting
Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)
NCT06497504· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)
NCT04954859· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
NCT03299049· Phase 3· ViiV Healthcare· Source
Active, not recruiting
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
NCT02951052· Phase 3· ViiV Healthcare· Source
Active, not recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
NCT02938520· Phase 3· ViiV Healthcare· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error